These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9517998)

  • 1. Long-term testosterone therapy in HIV-positive men: side-effects and maintenance of clinical benefit.
    Maguen S; Wagner GJ; Rabkin JG
    AIDS; 1998 Feb; 12(3):327-8. PubMed ID: 9517998
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
    Jani AB; Kao J; Hellman S
    Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone replacement in men.
    Beg S; Al-Khoury L; Cunningham GR
    Curr Opin Endocrinol Diabetes Obes; 2008 Aug; 15(4):364-70. PubMed ID: 18594278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone therapy can improve mood, energy.
    AIDS Alert; 1999 Feb; 14(2):18-20. PubMed ID: 11366173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J; Altwein JE
    Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement for hypogonadism: clinical findings and best practices.
    Hengge UR
    AIDS Read; 2003 Dec; 13(12 Suppl):S15-21. PubMed ID: 14959695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not enough test in testosterone. More and more men are turning to testosterone therapy even though little is known about its effects on the heart and long-term health.
    Harv Heart Lett; 2004 Apr; 14(8):1-2. PubMed ID: 15100080
    [No Abstract]   [Full Text] [Related]  

  • 9. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting.
    Grinspoon S; Corcoran C; Anderson E; Hubbard J; Stanley T; Basgoz N; Klibanski A
    Clin Infect Dis; 1999 Mar; 28(3):634-6. PubMed ID: 10194091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone therapy in the ageing male: what about the prostate?
    Schultheiss D; Machtens S; Jonas U
    Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of testosterone after menopause.
    Davis SR
    J Br Menopause Soc; 2004 Jun; 10(2):65-9. PubMed ID: 15207027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study.
    Pantanowitz L; Bohac G; Cooley TP; Aboulafia D; Dezube BJ
    BJU Int; 2008 Jun; 101(12):1519-23. PubMed ID: 18384640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
    Pickles T; Agranovich A; Berthelet E; Duncan GG; Keyes M; Kwan W; McKenzie MR; Morris WJ;
    Cancer; 2002 Jan; 94(2):362-7. PubMed ID: 11900222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV; Renshaw AA; Loffredo B; Chen MH
    Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 19. [Castration of prostate cancer patients and cognition].
    Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
    Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract]   [Full Text] [Related]  

  • 20. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
    Cella D; Fallowfield LJ
    Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.